Daré, a leader in women’s health innovation has recently announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period. It is being developed for the treatment of vasomotor symptoms (VMS)…
![](https://femtechinsider.com/wp-content/uploads/2021/03/dare-biosciences.jpg)